COVID-19 and SARS-CoV-2 Informational Resource Page
Menu
J&J Announce Promising Phase 3 Interim Analysis for Single-Dose COVID-19 Vaccine Candidate1/30/2021 Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination
85% Effective Overall in Preventing Severe Disease and Demonstrated Complete Protection Against COVID-19 related Hospitalization and Death as of Day 28 Protection Against Severe Disease Across Geographies, Ages, and Multiple Virus Variants, including the SARS-CoV-2 Variant from the B.1.351 Lineage [1] Observed in South Africa Single-shot compatible with standard vaccine distribution channels provides important tool in pandemic setting Press release link
0 Comments
Leave a Reply. |
AuthorJ. Kaiser, MSc
Categories |